Keywords: roche, actemra, inhibits, ra, joint, damage, boost
Roche's Actemra inhibits RA joint damage to boost QoL, according to Ph III LITHE data
Article | 19 May 2008
Late-stage trial data show that Roche's Actemra (tocilizumab) can significantly inhibit structural damage to joints in patients with rheumatoid arthritis, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
